We demonstrate the potent, selective, and sustained anti-tumor activity of these dual transgenic T cells in the IL4-rich breast cancer microenvironment and highlight the importance of transgenically delivering a combination of signals that recapitulate physiological T cell signaling (activation, co-stimulation, and cytokine support) to ensure durable benefit. Here, IL4 is linked to breast cancer.